A5103551721- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Chemotherapy-related skin toxicity
- Breast Lesions and Carcinomas
- Health Literacy and Information Accessibility
- Cancer and Skin Lesions
- BRCA gene mutations in cancer
- Social Media in Health Education
- Cancer-related Molecular Pathways
- Male Breast Health Studies
- AI in cancer detection
- Hair Growth and Disorders
- Cancer Diagnosis and Treatment
- Impact of Technology on Adolescents
- Digital Imaging in Medicine
- Nutrition and Health in Aging
- Nutritional Studies and Diet
- Multiple Myeloma Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- LGBTQ Health, Identity, and Policy
- Medical Imaging Techniques and Applications
European Institute of Oncology
2015-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
New School
2014
Ripamonti
2011-2013
Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging patients with early breast cancer (BC), but its necessity can be questioned since surgery examination nodes not performed curative intent.
Chemotherapy-induced alopecia (CIA) is a distressing side effect of cancer therapy. The trial aimed to assess feasibility and effectiveness scalp-cooling system DigniCap® prevent CIA in primary breast patients receiving an anthracycline containing adjuvant chemotherapy (CT). Hair loss (HL) was evaluated by patient self-assessment the physician according Dean's scale at baseline after each cycle CT. efficacy endpoint HL score least 3 weeks completing A 0–2 (i.e. ≤50%) considered success. From...
To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophosphamide as primary systemic treatment in locally advanced breast cancer.The activity and safety intravenous 20 mg sqm(-1) biweekly for eight courses combination 50 day(-1) orally were evaluated 29 patients cancer who not suitable to receive a standard chemotherapy due age or co-morbidities asked regimen low incidence toxic effects irrespective age.The rate breast-conserving surgery was 44.8%. Eighteen...
We collected information on 497 consecutive breast cancer patients aged less than 35 years operated at the European Institute of Oncology. The main aim study is to compare biological and clinical features dividing population by age: <25 years, 25–29 30–34 old. Pattern recurrence survival were also analyzed.Patients had 81.8% poorly differentiated tumors compared with 66.7% 56.5% in 30-34 groups, respectively; no other significant difference found distribution immunohistochemical Luminal A B,...
Few data are available on the benefit of metronomic cyclophosphamide, capecitabine, and vinorelbine as first-line therapy in patients with metastatic triple-negative breast cancer.This phase II study assessed safety efficacy oral chemotherapy 40 mg orally 3 times a week, cyclophosphamide 50 daily, capecitabine 500 day (VEX regimen) untreated cancer patients. The biopsy site had to be triple-negative, independent hormone receptor expression primary tumor. endpoint was time progression (TTP)....
PURPOSE The use of social media is transforming physician-patient communication, mainly in the field medical oncology. pattern by oncologists poorly studied. Therefore, we developed a survey to understand preferences, experiences, opinions, and expectations Italian oncology fellows regarding cancer medicine identify different profiles users. MATERIALS AND METHODS This multicentric, cross-sectional, observational study included or from Italy, who were surveyed July December 2023 on their...
Abstract Background Image-guided vacuum-assisted breast biopsy (VABB) of the tumour bed, performed after neoadjuvant therapy, is increasingly being used to assess residual cancer and potentially identify pathological complete response (pCR). In this study, accuracy preoperative VABB specimens was assessed compared with surgical in patients triple-negative or human epidermal growth factor receptor 2 (HER2)-positive invasive ductal therapy. As a secondary endpoint, performance...
Adjuvant chemotherapy for Luminal B-like breast cancers usually includes anthracycline-based regimens. However, some patients are reluctant to receive because of side-effects, especially alopecia, and ask a "less intensive" or personalized approach.We conducted phase II feasibility trial evaluate pegylated liposomal doxorubicin (PLD, Caelyx®) as adjuvant chemotherapy. Patients who received surgery pT1-3, any N, luminal early-stage cancer (EBC) candidates were included. PLD was administered...
Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Moreover, many chemotherapeutic agents need be interrupted due toxicity. Here we report an extremely long duration of chemotherapy eribulin (11 courses) in a taxane-pretreated patient. Therapy was well tolerated no worsening pre-existing neuropathy, achieving excellent outcomes good quality life. This adds the pool knowledge regarding use this important new agent.
Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2−) advanced breast cancer (ABC) the Phase 3b CompLEEment-1 trial. To evaluate of ribociclib Italian subpopulation with HR+, HER2− ABC from Patients received (600 mg/day, 3 weeks on/1 week off) (2.5 mg/day) while men premenopausal women additionally goserelin. were allowed ≤ 1 line prior chemotherapy an Eastern Cooperative...
Several studies have demonstrated that, following a breast cancer (BC) diagnosis, patients are eager to obtain information on and nutrition, in order ameliorate both their quality of life (QoL) disease outcome. To avoid BC survivors get wrong from unreliable sources, healthcare providers need be aware patients' needs, guide them toward optimal nutrition recommendations, aimed at preventing tumor recurrence increasing survival rates.
Abstract Background Adjuvant chemotherapy regimens for ‘Luminal B’ disease usually include anthracycline-based with or without taxanes. However, several patients are reluctant to receive because of toxic side-effects, especially alopecia, and ask a “less intensive” personalized approach. Methods We conducted single-center, phase II, single-arm, feasibility study evaluate pegylated liposomal doxorubicin (PLD, Caelyx®) as an adjuvant regimen in early-stage luminal B breast cancer (BC). The...
1059 Background: CDK4/6 inhibitors combined with endocrine therapy (ET) deeply transformed the treatment landscape of HR+/HER2− advanced breast cancer. After progression combination, there are no established guidelines for an optimal sequencing various therapeutic options. Data from randomized clinical trials (RCT) suggest that subsequent free survival (PFS2) was not compromised by use these drugs and time to chemotherapy (TTC) may be delayed. Therefore, we performed a meta-analysis evaluate...